The FDA has approved denileukin diftitox-cxdl (Lymphir, Citius) for the treatment of relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The immunotherapy is the only CTCL therapy that targets the interleukin (IL)-2 receptor found on malignant T cells and Tregs.
The efficacy of denileukin diftitox was evaluated in Study 302 (ClinicalTrials.gov. Identifier: NCT01871727), an open-label, single-arm, multicenter trial in patients with R/R
AUGUST 9, 2024